drugset / Trial / NCT06876701

The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

NCT06876701

Phase 0 Not yet recruiting 10 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults

Timeline

Start
2025-04-01
Primary completion
2027-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Other

Indications